AKTS · XBRL financial data
Aktis Oncology financial statements, every quarter
The same tables from 2 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters
| In thousands of dollars | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|
| Revenue | 3,227 | 3,384 |
| Research and development | 20,036 | 25,280 |
| General and administrative | 5,897 | 7,003 |
| Total operating expenses | 25,933 | 32,283 |
| Operating income (loss) | (22,706) | (28,899) |
| Interest income | 4,384 | 4,765 |
| Other income (expense) | (3) | (10) |
| Net income (loss) | (18,325) | (24,144) |
| Earnings per share, basic USD per share | (0.38) | (0.44) |
| Earnings per share, diluted USD per share | (0.38) | (0.44) |
| Weighted average shares, basic thousands of shares | 48,630 | 55,300 |
| Weighted average shares, diluted thousands of shares | 48,630 | 55,300 |
Balance sheet
CSVFiscal quarters
| In thousands of dollars | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|
| Cash and cash equivalents | 371,630 | 82,491 |
| Prepaid and other current assets | 5,456 | 7,219 |
| Total current assets | 543,940 | 524,539 |
| Property and equipment, net | 15,295 | 15,966 |
| Right-of-use asset | 12,816 | 12,230 |
| Total assets | 576,801 | 557,596 |
| Accounts payable | 1,227 | 2,533 |
| Accrued liabilities | 6,298 | 10,778 |
| Total current liabilities | 27,913 | 32,128 |
| Lease liability, non-current | 10,147 | 9,762 |
| Total liabilities | 70,693 | 72,758 |
| Accumulated deficit | (174,889) | (199,033) |
| Total stockholders' equity | 506,108 | 484,838 |
| Total liabilities and equity | 576,801 | 557,596 |
| Common shares outstanding (cover page) thousands of shares | 53,403 | 53,446 |
Cash flows
CSVFiscal quarters
| In thousands of dollars | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|
| Net income (loss) | (18,325) | (24,144) |
| Stock-based compensation | 3,022 | 3,222 |
| Depreciation and amortization | 652 | 879* |
| Net cash from operating activities | (24,242) | (20,587)* |
| Purchases of property and equipment | 1,854 | 1,262* |
| Net cash from investing activities | 20,541 | (268,708)* |
| Proceeds from issuing common stock | 5,376 | — |
| Net cash from financing activities | 337,547 | 156* |
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Aktis Oncology | 82,491 | 3,384 | (20,587)* | 53.4M | 4.0 quarters | 10-QJun 30, 2026 |
| 4D Molecular Therapeutics | 70,372 | 3,781 | (69,999)* | 55.2M | 6.2 quarters | 10-QJun 30, 2026 |
| Charlie's Holdings | 527 | not reported | (383)* | 280.6M | 1.4 quarters | 10-QJun 30, 2026 |
| CV Sciences | 266 | 2,985 | 20* | 225.8M | — | 10-QJun 30, 2026 |
| X4 Pharmaceuticals | 185,801 | 2,879 | (20,186)* | 102.1M | 9.2 quarters | 10-QSep 30, 2026 |
| Voyager Therapeutics | 48,408 | 4,014 | (19,666)* | 62.2M | 4.1 quarters | 10-QSep 30, 2026 |
| International Stem Cell | 1,089 | 2,675 | 167* | 8.0M | — | 10-QJun 30, 2026 |
| Evoke Pharma | 11,576 | 4,284 | (522)* | 1.7M | 22.2 quarters | 10-QSep 30, 2025 |
| Evofem Biosciences | 285 | 2,633 | (3,140)* | 132.5M | 0.1 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.